PVpharm will participate in the 42nd Pharmacovigilance India 2026, taking place on 23 July 2026 at the Radisson in Hyderabad.
The conference will bring together pharmacovigilance leaders, regulators, service providers, and pharmaceutical companies to discuss some of the key topics shaping the future of drug safety. The agenda includes artificial intelligence in pharmacovigilance, regulatory evolution, audit readiness, signal management, real-world evidence, risk management, and the growing role of India as a global hub for pharmacovigilance operations.
Jose Alberto Ayala Ortiz, CEO of PVpharm, will join the keynote panel discussion: “Future of Pharmacovigilance Outsourcing: Balancing Efficiency, Quality, and Compliance. India as a Global Hub for Pharmacovigilance Outsourcing.”
The session will be moderated by Siva Kumar Buddha from Amgen and will include panellists Prasad Deshmukh from Cipla, Rajesh Rajendran from Pfizer, Jose Alberto Ayala Ortiz from PVpharm, Sailaja Sayana from Sandoz, and Shubham Mittal from Nextrove.
Pharmacovigilance outsourcing continues to evolve as pharmaceutical companies face increasing operational complexity, higher regulatory expectations, and the need to manage safety information across multiple markets. In this context, outsourcing is no longer viewed only as a way to increase efficiency. It has become a strategic model that must combine expertise, quality systems, technology, compliance oversight, and a strong commitment to patient safety.
The panel will explore how companies can build effective outsourcing partnerships while maintaining robust governance and clear accountability. It will also address how India’s strong talent base, operational scale, and growing role in global pharmaceutical services are contributing to the transformation of pharmacovigilance outsourcing.
For PVpharm, this discussion is closely aligned with its experience supporting pharmaceutical companies with specialized pharmacovigilance services. As safety requirements continue to change, collaboration between sponsors, service providers, and regulators will remain essential to ensuring reliable, compliant, and patient-focused pharmacovigilance systems.
PVpharm looks forward to contributing to this important conversation and connecting with colleagues and industry experts in Hyderabad. Events such as Pharmacovigilance India 2026 offer a valuable opportunity to share practical insights, strengthen international collaboration, and reflect on the future of drug safety in an increasingly digital and global environment.
Link to agenda:
You can also contact us for any further information, we will be glad to assist you.
